Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
about
MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
P2860
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Topotecan and cisplatin in com ...... r Group (DOLG) phase II trial.
@ast
Topotecan and cisplatin in com ...... r Group (DOLG) phase II trial.
@en
type
label
Topotecan and cisplatin in com ...... r Group (DOLG) phase II trial.
@ast
Topotecan and cisplatin in com ...... r Group (DOLG) phase II trial.
@en
prefLabel
Topotecan and cisplatin in com ...... r Group (DOLG) phase II trial.
@ast
Topotecan and cisplatin in com ...... r Group (DOLG) phase II trial.
@en
P2093
P50
P1433
P1476
Topotecan and cisplatin in com ...... r Group (DOLG) phase II trial.
@en
P2093
Britta Bjerregaard Jensen
Peter Buhl Jensen
Seppo W Langer
Torben Palshof
P304
P356
10.1016/J.LUNGCAN.2007.09.022
P577
2007-11-26T00:00:00Z